CRISPR Therapeutics

CRISPR Therapeutics

Verified
Gene-based medicines for patients with serious diseases

Company information

Edit
Launch date
Employees
Ownership
Market cap
$4.2b
Net debt
$5.4b
Firm valuation
$5.3b (Public information from Jan 2022)
Revenues, earnings & profits over time
USD201620172018201920202021E2022E
Revenues-41m3m290m-904m12m
% growth--(93 %)9567 %--(99 %)
EBITDA-(61m)(155m)51m(345m)389m(726m)
% EBITDA margin-(149 %)(5167 %)18 %-43 %(6050 %)
Profit-(68m)(165m)66m(349m)387m(639m)
% profit margin-(166 %)(5500 %)23 %-43 %(5325 %)
EV / revenue-23.5x330.0x9.3x13420.0x6.3x229.0x
EV / EBITDA---6.6x52.0x-27.9x--4.0x
R&D budget--107m176m---
R&D % of revenue--3557 %61 %---

Source: Company fillings or news article

  • Edit
DateInvestorsAmountRound
-N/A-
Not yet verified
€22.5mSeries A
$64mSeries B
*
€38mSeries B
N/A$56m
Valuation: $626m
IPO
N/AN/AGrant
Not yet verified
Total Funding$131m

Recent News about CRISPR Therapeutics

Edit

Tech stack

Group
Tech stackLearn more about the technologies and tools that this company uses.